Related Experiment Video
Updated: Mar 6, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Identifying Drug-Drug Interactions by Data Mining: A Pilot Study of Warfarin-Associated Drug Interactions
Peter Wæde Hansen1, Line Clemmensen2, Thomas S G Sehested2
1From the Danish Heart Foundation, Copenhagen, Denmark (P.W.H., T.S.G.S., E.L.F., G.H.G.); DTU Compute, Technical University of Denmark, Lyngby (L.C.); The Heart Centre, Rigshospitalet (E.L.F., L.K.), and Department of Clinical Medicine (G.H.G.), University of Copenhagen, Denmark; Institute of Health, Science and Technology, Aalborg University, Denmark (C.T.-P.); The National Institute of Public Health, University of Southern Denmark, Copenhagen (G.H.G.); University of Copenhagen, Denmark; and Department of Medicine, Section of Cardiology, Glostrup Hospital, University of Copenhagen, Denmark (C.A.). Waede.sci@gmail.com.
Background:
Knowledge about drug-drug interactions commonly arises from preclinical trials, from adverse drug reports, or based on knowledge of mechanisms of action. Our aim was to investigate whether drug-drug interactions were discoverable without prior hypotheses using data mining. We focused on warfarin-drug interactions as the prototype.
Methods And Results:
We analyzed altered prothrombin time (measured as international normalized ratio [INR]) after initiation of a novel prescription in previously INR-stable warfarin-treated patients with nonvalvular atrial fibrillation. Data sets were retrieved from clinical work. Random forest (a machine-learning method) was set up to predict altered INR levels after novel prescriptions. The most important drug groups from the analysis were further investigated using logistic regression in a new data set. Two hundred and twenty drug groups were analyzed in 61 190 novel prescriptions. We rediscovered 2 drug groups having known interactions (β-lactamase-resistant penicillins [dicloxacillin] and carboxamide derivatives) and 3 antithrombotic/anticoagulant agents (platelet aggregation inhibitors excluding heparin, direct thrombin inhibitors [dabigatran etexilate], and heparins) causing decreasing INR. Six drug groups with known interactions were rediscovered causing increasing INR (antiarrhythmics class III [amiodarone], other opioids [tramadol], glucocorticoids, triazole derivatives, and combinations of penicillins, including β-lactamase inhibitors) and two had a known interaction in a closely related drug group (oripavine derivatives [buprenorphine] and natural opium alkaloids). Antipropulsives had an unknown signal of increasing INR.
Conclusions:
We were able to identify known warfarin-drug interactions without a prior hypothesis using clinical registries. Additionally, we discovered a few potentially novel interactions. This opens up for the use of data mining to discover unknown drug-drug interactions in cardiovascular medicine.
Related Concept Videos
Drug toxicity: Drug–Drug Interaction
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pharmacokinetics: Drug–Drug Interactions
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Drug toxicity: Idiosyncratic Reactions

